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osting by EAbstract Diabetic macular oedema (DMO) is a signiﬁcant cause of visual loss in the working pop-
ulation. Focal/grid photocoagulation remains an effective treatment for DMO and the benchmark
to which clinicians compare other newer treatment modalities. There are, however, patients who do
not respond adequately or who are refractory to laser photocoagulation. This has led to the devel-
opment of newer treatments such as the intravitreal injection of vascular endothelial growth factor
(VEGF) inhibitors as well as intravitreal corticosteroid releasing delivery systems. Cataract forma-
tion and raised intraocular pressure remain the major disadvantages of corticosteroid use. There is
mounting evidence that intravitreal VEGF inhibitors with or without combined laser photocoagu-
lation will become the gold standard treatment for DMO.
ª 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.Contents
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The global prevalence of people with diabetes is projected to
rise from 171 million in 2000 to 366 million in 2030. (Wild
et al., 2004) Much of this rise is due to changes in lifestyle
and the ageing population.
Using published prevalence data of visually threatening dia-
betic retinopathy, Saaddine et al. projected that the latter
would increase from 1.2 million in 2005 to 3.4 million in the
United States by 2050 (Saaddine et al., 2008).
Diabetic macular oedema (DMO) as a consequence of dia-
betes is a signiﬁcant cause of visual loss in the working popu-
lation (Bunce et al., 2008). The Wisconsin Epidemiological
Study of Diabetic Retinopathy looked at the twenty-ﬁve year
incidence of macular oedema in persons with type 1 diabetes.
They concluded that the 25 year cumulative incidence of mac-
ular oedema was 29% and was related mainly to glycemic con-
trol and blood pressure. (Klein et al., 2009).
Diagnosis of DMO has been facilitated with the advent of
investigations such as optical coherence tomography (OCT).
Panozzo et al. proposed a new classiﬁcation of diabetic macu-
lar oedema (DMO) based on OCT ﬁndings. This classiﬁcation
takes into account 5 parameters: retinal thickness, extension of
retinal thickening, macular volume, retinal morphology and
vitreo-retinal relationship. (Panozzo et al., 2004) OCT thick-
ness measurements are increasingly being used in the manage-
ment and monitoring of DMO.
The rationale for treating diabetic macular oedema is to
prevent lipids accumulating at the fovea, minimise permanent
structural damage secondary to clinically signiﬁcant macular
oedema and stabilise visual acuity.
Before considering the current and future treatments for
DMO, it is useful to consider the inﬂammatory mediators that
could potentially be targeted. Poulaki et al. demonstrated the
involvement of IGF-1 in the pathogenesis of diabetic retinop-
athy and its downstream signalling pathways which involve the
stimulation of Vascular Endothelial Growth Factor (VEGF)
gene expression (Poulaki et al., 2004).
Aiello et al. previously demonstrated that protein kinase C
(PKC) is an important intracellular signalling pathway follow-
ing activation of VEGF. Studies in rats illustrated that there
was reduction in VEGF induced permeability by PKC inhibi-
tors (Aiello et al., 2006). Other groups have conﬁrmed that
inhibition of classical PKC isoforms, such as PKC b, reduced
VEGF induced permeability by approximately half (Harhaj
et al., 2006).
Mammalian target of rapamycin (mTOR) is a further pro-
tein kinase that maintains multiple cellular pathways, includ-
ing those involved in inﬂammation and angiogenesis. The
development of mTOR inhibitors has proven to be effectivein the down-regulation of VEGF and thus angiogenesis in
DMO.
Due to marked success with VEGF inhibitors in the man-
agement of neovascular age related macular degeneration
and the known elevated intravitreal VEGF levels in patients
with diabetic retinopathy (Adamis et al., 1994), researches
and clinicians turned their attention to the use of these agents
in the management of leakage and/or neovascularisation in
diabetic eye disease. It has been well established that VEGF
165 is linked to retinal intercellular adhesion molecule (ICAM)
-1, which in turn induces retinal leukostasis and blood retinal
barrier breakdown, thus resulting in retinal angiogenesis and
increased vascular permeability (Ishida et al., 2003).
Within this article, we shall discuss current treatments in
the management of DMO. In addition, we shall review newer
emerging therapies in combating this disabling condition.
2. Laser photocoagulation
The mainstay and benchmark to which newer treatments are
compared is laser photocoagulation.
The Early Treatment Diabetic Retinopathy Study (ETDRS)
was a landmark trial that established laser photocoagulation as
a treatment for clinically signiﬁcant diabetic macular oedema,
deﬁned as one or more of the following: (1) Retinal thickening
at or within 500 lm of the fovea. (2) Hard exudates at or within
500 lm of the fovea if associated with adjacent retinal thicken-
ing. (3) An area of retinal thickening one disc area in size, at
least part of which is within one disc diameter of the fovea.
2244 patients were randomly assigned to receive either early
treatment with focal and grid photocoagulation or deferral of
photocoagulation Data from this trial demonstrated that focal
photocoagulation of clinically signiﬁcant diabetic macular oe-
dema substantially reduced the risk of future visual loss.
Nevertheless, visual recovery within patients with clinically
signiﬁcant diabetic macular oedema is harder to achieve and
the ETDRS demonstrated that despite successful treatment
and reduction in central retinal thickness, only 17% of patients
recovered 3 or more lines (Anon, 1985).
In 2007, the DRCRnet group carried out a randomised
control trial on 323 eyes comparing mild macular grid laser
and conventional modiﬁed ETDRS direct/grid laser for
DMO. Mild macular grid laser involved delivering barely vis-
ible 50 lm diameter burns to the whole macula, regardless of
localized thickening or microaneurysms. At 12 months, only
22% of eyes receiving mild macular grid treatment showed a
reduction over 0.6 disc diameters of retinal thickening, com-
pared to 31% in the conventional treatment group
(p= 0.03). The visual acuity outcome between the two groups
was not substantially different (Fong et al., 2007).
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theoretically avoids damaging the inner neurosensory retina.
This potentially may reduce complications, such as paracen-
tral scotomas and scarring post treatment (Akduman and
Olk, 1999). Figueira et al. carried out a prospective random-
ised controlled trial comparing sub-threshold micropulse
diode laser photocoagulation and conventional green argon
laser in 84 eyes. This group demonstrated that at 12 months
there was no statistically signiﬁcant difference in visual acuity
(p= 0.88), macular thickness (p= 0.81) or contrast sensitiv-
ity (p= 0.87) between the study groups (Figueira et al.,
2009).
Vujosevic et al. carried out a prospective randomised trial
on 62 eyes of 50 patients undergoing either subthreshold
micropulse diode or modiﬁed ETDRS photocoagulation for
DMO, evaluating microperimetry and fundus autoﬂuorescence
(FAF) pre and post treatment. At 12 months follow-up, this
study demonstrated no clinical difference between the two
groups with regard to best corrected visual acuity and mean
central retinal thickness. However, micropulse diode laser
treatment did not determine any change on FAF. The group
concluded that microperimetry data encouraged the use of a
new, less aggressive laser therapeutic approach in the treat-
ment of clinically signiﬁcant DMO (Vujosevic et al., 2010).
However, the precise optimum treatment parameters of
micropulse diode have not yet been established and its use
has not been adopted in a widespread manner.
3. Intravitreal steroids
In 2008, DRCRnet carried out a multi-centre randomised con-
trolled trial involving 840 eyes, comparing modiﬁed ETDRS
laser photocoagulation with either 1 mg or 4 mg of preserva-
tive-free intravitreal triamcinolone. All patients were eligible
for re-treatment at 4 monthly intervals if oedema persisted.
At 4 months, mean visual acuity was better in the 4 mg group
compared to both the 1 mg triamcinolone and laser groups
(p< 0.001). Interestingly, at 1 year, there were no signiﬁcant
differences in mean visual acuity between the groups. At
16 months (and extending to 2 years), mean visual acuity was
better in the laser group than in the other 2 groups. The
OCT results paralleled the visual acuity results, with the
4 mg traimcinolone group demonstrating a greater beneﬁcial
effect at the 4 month visit compared to the other two groups.
During the second year, there was a greater beneﬁcial effect
in the laser group, compared with the other two groups. This
study further demonstrated with subanalysis of pseudophakic
patients that cataract was not a confounding factor, conﬁrm-
ing a beneﬁcial effect in the laser group despite lens status
(Anon, 2008). Three-year follow-up of 306 eyes was reported
in 2009. Change in visual acuity letter score from baseline to
3 years was +5 in the laser group and 0 in each trimcinolone
group. The 3 year cumulative probability of having cataract
surgery was 31% in the laser group, 46% in the 1 mg group
and 83% in the 4 mg group (p< 0.001 for all pairwise com-
parisons). It should be noted that a limitation to this study
was the completeness to longer-term follow-up with only a co-
hort of 36% of patients being able to achieve the 3 year follow-
up (Beck et al., 2009).
In 2009, Gillies carried out a study in 69 eyes comparing the
5 year outcomes of intravitreal triamcinolone with placebo fordiabetic macular oedema. Five year data was only available for
66% of the group. Improvement ofP5 letters after 5 years was
found in 42% initially treated with intravitreal triamcinolone
compared to 32% initially treated with placebo., but this ﬁnd-
ing was not statistically signiﬁcant (p= 0.4). There was also
no difference in the mean central macular thickness reduction
between the two groups (Gillies et al., 2009).
Various studies have looked at the role of intravitreal tri-
amcinolone (IVTA) as an adjunct to focal macular laser
(Lam et al., 2007; Gillies et al., 2010). Gillies et al. carried
out a prospective, double-masked placebo controlled trial
comparing 4 mg IVTA versus placebo 6 weeks prior to laser
photocoagulation for DMO. Improvement in P5 letters of
BCVA was no different between the two groups (p= 0.807)
despite a mean 50 lm reduction in central macular thickness
in the IVTA group compared to the control group at 6 months
(p= 0.016) (Gillies et al., 2010). The DRCRnet compared fo-
cal macular photocoagulation 4 weeks after sub-tenon’s injec-
tion of 40 mg triamcinolone to laser alone. There were no
statistical differences between any group in terms of visual acu-
ity (p= 0.94) or central retinal thickness (p= 0.46) (Chew
et al., 2007).
Recently, the advent of intravitreal biodegradable drug
delivery systems has proved of interest in the management of
DMO. Haller et al. (2010) compared the use of a 700 lg dexa-
methasone intravitreal drug delivery system, 350 lg dexameth-
asone intravitreal drug delivery system and observation (171
eyes, 57 in each group, 180 day follow-up) for the treatment
of DMO. At 90 day follow-up, a statistically signiﬁcant differ-
ence in the proportion of eyes achieving at least a 10-letter
improvement in BCVA was evident between the 700 lg dexa-
methasone group and the observation group (33% vs. 12%;
p= 0.007). This difference was not statistically signiﬁcant at
day 180. At 60 day follow-up, a statistically signiﬁcant differ-
ence in the proportion of eyes achieving at least a 10-letter
improvement in BCVA was evident between the 350 lg dexa-
methasone DDS group and the observation group (23% vs.
9%; p= 0.04). This difference was not statistically signiﬁcant
at day 90 or day 180. At day 90, there was a statistically signif-
icant improvement in both central retinal thickness (p< 0.01)
and ﬂuorescein leakage (p< 0.001) in eyes that received the
700 lg dexamethasone DDS compared with eyes in the obser-
vation group. The 350 lg dexamethasone DDS group also
demonstrated an improvement in ﬂuorescein leakage com-
pared to observation at day 90 (p= 0.03). This group did
not show a statistically signiﬁcant improvement in central ret-
inal thickness at day 90 (Haller et al., 2010).
Fluocinolone acetonide has been recently developed as a
non-biodegradable intravitreal insert (IluvienTM) with sus-
tained release of ﬂuocinolone for up to 36 months for treat-
ment of DMO. The ongoing FAME study includes 956
patients randomised to receive either a low dose ﬂuocinolone
insert, a high dose ﬂuocinolone insert or a sham injection. At
24 months, preliminary results demonstrate an improvement
in the best corrected visual acuity (BCVA) of 15 or more letters
of 26.8% and 26.0% in the low and high dose patients respec-
tively (Figueira, 2010).
Other emerging steroid drug delivery systems in develop-
ment include a triamcinolone acetonide trans-scleral helical
implant (I-vation) (ClinicalTrials.gov: NCT00915837). The re-
sults of these trials are awaited.
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ment of cataract and elevation of intraocular pressure (Gillies
et al., 2004; Quiram et al., 2006).4. Intravitreal VEGF inhibitors
Many trials and studies have demonstrated that inhibition of
VEGF using agents, such as pegaptanib, bevacizumab and
ranibizumab has shown dramatic improvements in resolution
of DMO and improvement in visual acuity.
Pegaptanib (macugen) has previously been investigated
using a randomised control trial in 172 eyes. This latter study
compared different doses of Pegaptanib (0.3 mg, 1 mg, 3 mg)
versus each other and sham injection at study entry, week 6
and week 12. Additional injections and/or laser could be given
as required for another 18 weeks after week 12. At week 36, all
3 Pegaptanib subgroups had better visual acuity than the sham
group. At week 36, the median visual acuity was better with
0.3 mg group as compared with sham (p= 0.04). In addition,
mean central retinal thickness decreased by 68 lm in the
0.3 mg group, versus an increase of 4 lm in the sham group
(p= 0.02). There was no statistical difference between the Peg-
aptanib doses, although the authors attributed this to small
numbers within the study (Cunningham et al., 2005). Further
studies assessing the effect of pegaptanib are underway.
The READ-2 study compared the effect of intravitreal
0.5 mg ranibizumab versus laser photocoagulation versus com-
bined ranibizumab and laser photocoagulation in 126 eyes.
This latter study demonstrated that the mean gain in best cor-
rected visual acuity was signiﬁcantly better in the ranibizumab
group compared to the laser photocoagulation group
(p= 0.0001) at 6 months. There was no statistically signiﬁcant
difference between the ranibizumab group and the combina-
tion group (Nguyen et al., 2009).
Massin et al. (2010) recently published the RESOLVE
study – a randomised controlled double masked, multicenter
phase II study evaluating the safety and efﬁcacy of rani-
bizumab in the treatment of DMO at 12 months. Patients were
randomised to three treatment arms: 0.3 mg ranibizumab,
0.5 mg ranibizumab or sham injection and received three
monthly injections. Thereafter, all patients could receive laser
photocoagulation if required depending on speciﬁed treatment
criteria.. After month 1, the ranibizumab dose could be dou-
bled by increasing the injection volume from 0.05 ml to
0.1 ml if the central retinal thickness was >300 lm or was
>225 lm and the reduction in retinal oedema from the previ-
ous assessment was <50 lm. At 12 months, the ranibizumab
treatment arms had a mean gain of 10.3 letters compared to
the sham group, which had a mean decline of 1.4 letters
(p< 0.0001). In addition, the mean central retinal thickness
reduced by 194.2 lm compared to 48.4 lm with sham injection
(p< 0.0001) (Massin et al., 2010).
A phase III study evaluating the efﬁcacy and safety of rani-
bizumab in patients with visual impairment due to DMO (RE-
STORE) is currently underway. This is a randomised, double-
masked, multicenter trial with three treatment arms: rani-
bizumab 0.5 mg in addition to sham laser, ranibizumab in
addition to active laser, and sham injection in addition to ac-
tive laser. Over one year, patients treated with combination
ranibizumab and laser were able to read a mean average addi-tional 5.9 letters. Those who received monotherapy rani-
bizumab alone could read mean average 6.1 letters more
than at the start of the study. This compared to a mean aver-
age gain of 0.8 letters in patients who received laser therapy
alone (p< 0.0001) (Schlinge, 2010).
In 2010, a landmark DRCR.net study compared 0.5 mg
intravitreal ranibizumab with prompt focal/grid laser photoco-
agulation, 0.5 mg ranibizumab with deferred laser photocoag-
ulation (at least 24 weeks later), 4 mg intravitreal
triamcinolone with prompt laser or a sham injection with
prompt laser. This study demonstrated that at 1 year, 0.5 mg
intravitreal ranibizumab combined with either prompt or de-
ferred laser photocoagulation, showed superior improvements
in best corrected visual acuity (BCVA) compared with laser
treatment alone. The group treated with 4 mg intravitreal tri-
amcinolone with prompt laser did not demonstrate a signiﬁ-
cant improvement in BCVA compared with laser alone.
However, this group did result in a greater reduction in retinal
thickness on OCT. compared with the laser group. It should be
noted that when a subgroup analysis was carried out on the
pseudophakic patients in the triamcinolone group, there was
an improvement in BCVA similar to that of the ranibizumab
group, suggesting that the initial ﬁnding of no signiﬁcant
BCVA improvement in the whole triamcinolone group may
have been the result of cataract formation in phakic patients
(Elman et al., 2010).
Lam et al. compared the efﬁcacy of 3 monthly injections of
1.25MG versus 2.5MG of intravitreal bevacizumab for dia-
betic macular oedema in 52 eyes. Signiﬁcant reduction in mean
central foveal thickness was observed in both groups at all fol-
low-up visits (p< 0.013). At 6 month follow-up, the mean log-
MAR BCVA improved from 0.63 to 0.52 in the 1.25 mg group
and 0.60 to 0.47 in the 2.5 mg group and thus no signiﬁcant
difference in BCVA was observed between the 2 groups at
any time point (Lam et al., 2009). In 2008, Ahmadieh et al. car-
ried out a randomised controlled trial comparing three injec-
tions of 1.25 mg intravitreal bevacizumab versus combined
1.25 mg intravitreal bevacizumab and 2 mg intravitreal triam-
cinolone, followed by two injections of intravitreal bev-
acizumab at 6-week intervals versus sham injection. A total
of 115 eyes were recruited. At week 24, central macular thick-
ness was reduced signiﬁcantly in both the intravitreal bev-
acizumab group (p= 0.012) and the combined intravitreal
bevacizumab and intravitreal triamcinolone group
(p= 0.022) compared to the sham group. With regard to vi-
sual acuity change from baseline to week 24, there was a signif-
icant difference between combined intravitreal bevacizumab
and intravitreal triamcinolone group and the sham group
(p= 0.006) as well as a signiﬁcant difference between the
intravitreal bevacizumab group and the sham group
(p= 0.01). There were no signiﬁcant changes detected between
both treatment groups, although the combination group dem-
onstrated an earlier beneﬁcial effect (Ahmadieh et al., 2008).
Scott et al. compared 1.25 mg intravitreal bevacizumab at
baseline and 6 weeks, versus 2.5 mg bevacizumab at baseline
and at 6 weeks, versus 1.25 mg bevacizumab at baseline and
sham injection at 6 weeks, versus laser photocoagulation ver-
sus combination 1.25 mg bevacizumab at baseline and 6 weeks
and laser photocoagulation at 3 weeks in 121 eyes. This group
established the 1.25 mg intravitreal bevacizumab and the
2.5 mg bevacizumab groups both demonstrated a greater
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< 0.001, respectively) compared with laser photocoagulation.
This ﬁnding was not maintained through to 12 weeks. The lat-
ter groups also demonstrated a median one line improvement
at 3 weeks which was sustained through to 12 weeks, as com-
pared with the laser group (p= 0.01 and 0.003, respectively).
The combination of bevacizumab and laser demonstrated no
short term beneﬁts (Scott et al., 2007).
A further randomised controlled trial involving 150 eyes
with a follow-up of 36 weeks compared 1.25 mg intravitreal
bevacizumab versus 1.25 mg intravitreal bevacizumab and
2 mg intravitreal triamcinolone versus macular laser photoco-
agulation. Retreatment was performed at 12-week intervals
when required. Compared with baseline, visual acuity
improvement was signiﬁcantly better in the intravitreal bev-
acizumab group at all follow-up visits up to 36 weeks
(p< 0.001). In the combined intravitreal bevacizumab and
intravitreal triamcinolone group, visual acuity improved sig-
niﬁcantly only at weeks 6 and 12 (p= 0.002 and 0.019, respec-
tively). In the macular photocoagulation group, visual acuity
did not signiﬁcantly change compared to baseline (Soheilian
et al., 2009). More recently Michaelides et al. carried out a pro-
spective randomized trial of intravitreal bevacizumab or laser
therapy in the management of diabetic macular edema (BOLT
Study). Patients were randomised to either intravitreal bev-
acizumab (6 weekly; minimum of three injections and maxi-
mum of nine injections in the ﬁrst 12 months) or laser
photocoagulation (four monthly; minimum of one treatment
and maximum of four treatments in the ﬁrst 12 months). The
bevacizumab group gained a median of 8 ETDRS letters com-
pared to the laser group which lost a median of 0.5 ETDRS
letters (p= 0.0002). This correlated with the reduction in cen-
tral retinal thickness at 12 months (Michaelides et al., 2010).5. Other potential treatments
5.1. VEGF165b
VEGF165b is an endogenous molecule expressed in human
retina, vitreous and iris (Perrin et al., 2005). It inhibits
VEGF165 mediated angiogenesis and is, therefore, anti-angio-
genic. Konopatskaya et al demonstrated using a mouse model
that a single intraocular injection of VEGF1b can signiﬁcantly
reduce pre-retinal neovascularisation. This group hypothesised
that controlling the balance of VEGF165 and VEGF165b, by
regulating the splicing between the isoforms may be a valuable
method for treating diabetic eye disease in future (Konopats-
kaya et al., 2006). In addition, animal models have shown that
VEGF165b confers no inhibition of physiological angiogene-
sis, permitting this process to proceed normally (Konopats-
kaya et al., 2006; Stitt et al., 2005).
VEGF165b is an exciting novel addition to this arena and
perhaps the control of endogenous VEGF165b will provide a
useful target in future.5.2. PKC inhibitors
Davis et al. carried out a prospective randomised trial evaluat-
ing the effect of the PKC inhibitor (Ruboxistaurin) compared
to placebo in treating DMO. 685 patients were recruited with
follow-up to 36 months. Moderate visual loss occurred in5.5% of ruboxistaurin treated patients compared to 9.1% of
placebo treated patients (p= 0.034)). In addition, treatment
with ruboxistaurin was also associated with less progression
of DMO to within 100 lm of the macular centre in eyes with
CSMO at baseline and with less frequent laser photocoagula-
tion (Aiello et al., 2006). Further trial results are awaited
and the drug is not currently available for use in diabetic
retinopathy.
5.3. mTOR inhibitors
The mTOR inhibitor sirolimus (rapamycin) has been devel-
oped as a potential treatment for both neovascular age related
macular degeneration (nAMD) as well as DMO, due to its
ability to inhibit inﬂammation and angiogenesis. Sirolimus
inhibits hypoxia-inducible factor-1 alpha (HIF-1a) involved
in activating angiogenesis and hyper-permeability in addition
to stimulating VEGF (Dutcher, 2004; Hudson et al., 2002).
Trials using Sirolimus for both DMO and nAMD are
underway.
5.4. VEGF-TRAP
VEGF-TRAP is a soluble VEGF receptor fusion protein that
binds to all isoforms of VEGF-A as well as placental growth
factor. It has a higher binding afﬁnity compared to that of
ranibizumab and bevacizumab and thus has a longer duration
of action (Do et al., 2009; Kaiser, 2009). Interestingly, Stewart
et al. demonstrated that 79 days after a single VEGF Trap
(1.15 mg) injection, the intravitreal VEGF-binding activity
would be comparable to ranibizumab at 30 days (Stewart
and Rosenfeld, 2008). This is a key advantage due to the chro-
nicity of DMO as well as the burden associated with regular
intravitreal VEGF inhibitor injections.
A double-masked randomized controlled study evaluating
the safety and efﬁcacy of intravitreal VEGF Trap-Eye in pa-
tients with DMO is in progress (ClinicalTrials.gov:
NCT00789477).6. Conclusions
We are entering a new era with regard to the management of
DMO. Until recently, laser photocoagulation has been the
mainstay of treatment and the benchmark to which we com-
pare all treatments of DMO. However, there is growing evi-
dence that intravitreal VEGF inhibitors (with or without) in
combination with laser photocoagulation will become the gold
standard of therapy to add to our armamentarium when com-
bating DMO.References
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